Shionogi agrees $2bn acquisition of IntraBio to expand rare disease portfolio
Shionogi has agreed to acquire IntraBio for $2 billion, adding the rare neurological disease therapy AQNEURSA and its global commercial rights to the Japanese group's portfolio.
The acquisition gives Shionogi ownership of IntraBio and AQNEURSA (levacetylleucine), which is approved for rare neurological disorders including Niemann-Pick disease type C and ataxia associated with ataxia-telangiectasia.
The transaction is expected to close in November or December 2026, subject to customary regulatory conditions, and materially expands Shionogi's presence in rare neurological diseases.
Field | Content |
Article Type | Deals |
Companies | Shionogi; IntraBio |
Deal Type | Acquisition |
Acquired Company | IntraBio |
Transaction Value | $2 billion upfront |
Key Asset | AQNEURSA (levacetylleucine) |
Therapy Areas | Rare disease; neurology |
Technology/Modality | Small-molecule therapy |
Transaction Scope | 100% acquisition of IntraBio, including global intellectual-property and commercial rights to AQNEURSA |
Expected Closing | November-December 2026 |
What Happened | Shionogi agreed to acquire 100% of IntraBio for $2 billion upfront. |
Why It Matters | The acquisition adds an established rare-neurology commercial asset and specialist rare-disease capabilities to Shionogi's portfolio. |
Supporting Context | AQNEURSA is approved in the US and EU for neurological manifestations of Niemann-Pick disease type C and has also received FDA approval for ataxia in patients with ataxia-telangiectasia. |
Strategic Rationale | Shionogi is strengthening its rare-disease and neurological portfolio through ownership of IntraBio's products, intellectual property and commercial capabilities. |
Potential Impact | The transaction could accelerate Shionogi's expansion in rare neurological diseases while supporting broader commercial development of AQNEURSA. |
Key Takeaway | Shionogi is acquiring IntraBio for $2 billion to add AQNEURSA and expand its rare-disease business. |
What to Watch | Transaction closing, integration of IntraBio and future geographic or indication expansion for AQNEURSA. |
Primary Source | Shionogi |
Relevant Date | 5 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentários